OTCM
RBGLY
Market cap42bUSD
Sep 17, Last price
13.52USD
1D
-1.17%
1Q
8.77%
Jan 2017
-22.82%
IPO
69.49%
Name
Reckitt Benckiser Group PLC
Chart & performance
P/E
2.02
P/S
0.45
EPS
5.01
Div yield, %
4.06%
Shrs. gr., 5y
-1.74%
Rev. gr., 5y
0.30%
Revenues
14.21b
+0.25%
Net income
3.18b
+123.14%
CFO
2.30b
-14.35%
Dividend
Aug 10, 20260.23562 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Related entities
Subsidiaries (65)
CANTERBURY SQUARE HOLDINGS S.A R.L.
ERB TRADING LIMITED
LANCASTER SQUARE HOLDINGS SL
LONDON INTERNATIONAL TRADING (ASIA) LIMITED
MEAD JOHNSON DO BRASIL COMÉRCIO E IMPORTAÇÃO DE PRODUTOS DE NUTRIÇÃO LTDA
MEAD JOHNSON NUTRICIONALES DE MEXICO, S. DE R.L. DE C.V.
MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.
MEAD JOHNSON NUTRITION (CANADA) CO.
MEAD JOHNSON NUTRITION (INDIA) PRIVATE LIMITED
MEAD JOHNSON NUTRITION (PHILIPPINES), INC.
MEAD JOHNSON NUTRITION (VIETNAM) COMPANY LIMITED
MEAD JOHNSON NUTRITION COLOMBIA LTDA
MJN INTERNATIONAL HOLDINGS (UK), LTD.
RB (HEALTH) COLOMBIA S.A.S.
RB (HEALTH) MALAYSIA SDN. BHD.
RB HEALTH PERU S.R.L.
RB SALUTE MEXICO SA DE CV
RECKITT BENCKISER (BRASIL) LTDA.
RECKITT BENCKISER (HEALTH) HOLDINGS LIMITED
RECKITT BENCKISER (INDIA) PRIVATE LIMITED
Branches
BELEGGINGSMAATSCHAPPIJ LEMORE B.V.
Key people
Non-Executive Independent Director · since 2025
Designated Non-Executive Independent Director · since 2024
Headquarters & legal address
103-105 BATH ROAD
SLOUGH, SLG SL1 3UH
GB
SLOUGH, SLG SL1 3UH
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||